Research status of RAS/ERK signaling pathway in neurofibromatosis

doi:10.3760/cma.j.issn.1007-1245.2023.05.001

Abstract

Abstract:

Neurofibromatosis (NF) is a hereditary disease involving the nervous tissues of the central and peripheral nervous systems, which can be classified as neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and Schwannomatosis (SWN). Previous studies have shown that rat sarcoma protein/extracellular signal-regulated protein kinase (RAS/ERK) signaling pathway is abnormally expressed in many types of tumor tissues. At the same time, our research group has also found similar results in the preliminary experimental studies of familial NF. In order to further explore the link between RAS/ERK signaling pathway and NF, this paper reviews the current research status of RAS/ERK signaling pathway in NF.

Key words:

Neurofibromatosis, Cell signaling pathway, Pathogenesis

摘要：

神经纤维瘤病（NF）是一种累及中枢及周围神经系统神经组织的遗传性疾病，可分为1型神经纤维瘤病（NF1）、2型神经纤维瘤病（NF2）及神经鞘瘤病（SWN）。现有研究表明，大鼠肉瘤蛋白/细胞外信号调节蛋白激酶（RAS/ERK）信号通路在许多类型肿瘤组织中存在异常表达。同时，我们课题组在对家族性NF的前期实验研究中也发现相似结果。为进一步探索RAS/ERK信号通路与NF的联系，笔者对NF中RAS/ERK信号通路的研究现况进行回顾并作出综述。

关键词:

神经纤维瘤病, 细胞信号通路, 发病机制

Fu Zhixiong, Zhang Ancheng, Yang Yongjian, Guo Weitao.

Research status of RAS/ERK signaling pathway in neurofibromatosis [J]. International Medicine and Health Guidance News, 2023, 29(5): 593-597.

符志雄张桉铖杨永键郭伟韬.

RAS/ERK信号通路在神经纤维瘤病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(5): 593-597.

References

[1] Kresak JL, Walsh M. Neurofibromatosis: a review of NF1, NF2, and Schwannomatosis[J]. J Pediatr Genet, 2016, 5(2): 98-104. DOI: 10.1055/s-0036-1579766.
[2] Wittinghofer A. Signal transduction via Ras[J]. Biol Chem, 1998, 379(8-9): 933-937.
[3] Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective[J]. Lancet Neurol, 2007, 6(4): 340-351. DOI: 10.1016/S1474-4422(07)70075-3.
[4] Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP[J]. Cell, 1990, 62(3): 599-608. DOI: 10.1016/0092-8674(90)90024-9.
[5] Stanbridge EJ. Human tumor suppressor genes[J]. Annu Rev Genet, 1990, 24: 615-657. DOI: 10.1146/annurev.ge.24.120190.003151.
[6] Trahey M, McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants[J]. Science, 1987, 238(4826): 542-545. DOI: 10.1126/science.2821624.
[7] Tanaka K, Nakafuku M, Satoh T, et al . Cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating protein[J]. Cell, 1990, 60(5): 803-807. DOI: 10.1016/0092-8674(90)90094-u.
[8] Marshall MS, Hill WS, Ng AS, et al. A C-terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity[J]. EMBO J, 1989, 8(4): 1105-1110. DOI: 10.1002/j.1460-2075.1989.tb03480.x.
[9] Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction[J]. Bioessays, 2000, 22(5): 442-451. DOI: 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q.
[10] Dai Z, Quackenbush RC, Courtney KD, et al. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway[J]. Genes Dev, 1998, 12(10): 1415-1424. DOI: 10.1101/gad.12.10.1415.
[11] Cichowski K, Santiago S, Jardim M, et al. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor[J]. Genes Dev, 2003, 17(4): 449-454. DOI: 10.1101/gad.1054703.
[12] Hollstein PE, Cichowski K. Identifying the ubiquitin ligase complex that regulates the NF1 tumor suppressor and Ras[J]. Cancer Discov, 2013, 3(8): 880-893. DOI: 10.1158/2159-8290.CD-13-0146.
[13] Kato R, Nonami A, Taketomi T, et al. Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated erk activation[J]. Biochem Biophys Res Commun, 2003, 302(4): 767-772. DOI: 10.1016/s0006-291x(03)00259-6.
[14] Gertler FB, Niebuhr K, Reinhard M, et al. Mena, a relative of VASP and Drosophila Enabled, is implicated in the control of microfilament dynamics[J]. Cell, 1996, 87(2): 227-239. DOI: 10.1016/s0092-8674(00)81341-0.
[15] Stowe IB, Mercado EL, Stowe TR, et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1[J]. Genes Dev, 2012, 26(13): 1421-1426. DOI: 10.1101/gad.190876.112.
[16] Scheffzek K, Ahmadian MR, Wiesmüller L, et al. Structural analysis of the GAP-related domain from neurofibromin and its implications[J]. EMBO J, 1998, 17(15): 4313-4327. DOI: 10.1093/emboj/17.15.4313.
[17] Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients[J]. Nature, 1992, 356(6371): 713-715. DOI: 10.1038/356713a0.
[18] Packer RJ, Gutmann DH, Rubenstein A, et al. Plexiform neurofibromas in NF1: toward biologic-based therapy[J]. Neurology, 2002, 58(10): 1461-1470. DOI: 10.1212/wnl.58.10.1461.
[19] Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors[J]. J Clin Invest, 2013, 123(1): 340-347. DOI: 10.1172/JCI60578.
[20] Gross AM, Frone M, Gripp KW, et al. Advancing RAS/RASopathy therapies: an NCI-sponsored intramural and extramural collaboration for the study of RASopathies[J]. Am J Med Genet A, 2020, 182(4): 866-876. DOI: 10.1002/ajmg.a.61485.
[21] 彭词艳,陈景,李斯妮,等. 治疗神经纤维瘤病新药——丝裂原活化蛋白激酶抑制剂Selumetinib[J]. 肿瘤药学,2021,11(3):280-283. DOI:10.3969/j.issn.2095-1264.2021. 03.05.
[22] Evans DG. Neurofibromatosis 2 Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II] [J]. Genet Med, 2009, 11(9): 599-610. DOI: 10.1097/GIM.0b013e3181ac9a27.
[23] Stamenkovic I, Yu Q. Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival[J]. Curr Protein Pept Sci, 2010, 11(6): 471-484. DOI: 10.2174/138920310791824011.
[24] Hilton DA, Ristic N, Hanemann CO. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ[J]. Histopathology, 2009, 55(6): 744-749. DOI: 10.1111/j.1365-2559.2009.03440.x.
[25] Yan W, Markegard E, Dharmaiah S, et al. Structural insights into the SPRED1-neurofibromin-KRAS complex and disruption of SPRED1-neurofibromin interaction by oncogenic EGFR[J]. Cell Rep, 2020, 32(3): 107909. DOI: 10.1016/j.celrep.2020.107909.
[26] Cui Y, Groth S, Troutman S, et al. The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling[J]. Oncogene, 2019, 38(36): 6370-6381. DOI: 10.1038/s41388-019-0883-6.
[27] Cui Y, Ma L, Schacke S, et al. Merlin cooperates with neurofibromin and Spred1 to suppress the Ras-Erk pathway[J]. Hum Mol Genet, 2021, 29(23): 3793-3806. DOI: 10.1093/hmg/ddaa263.
[28] Doherty JK, Ongkeko W, Crawley B, et al. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy[J]. Otol Neurotol, 2008, 29(1): 50-57. DOI: 10.1097/mao.0b013e31815d4429.
[29] Lallemand D, Manent J, Couvelard A, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas[J]. Oncogene, 2009, 28(6): 854-865. DOI: 10.1038/onc.2008.427.
[30] Houshmandi SS, Emnett RJ, Giovannini M, et al. The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner[J]. Mol Cell Biol, 2009, 29(6): 1472-1486. DOI: 10.1128/MCB.01392-08.
[31] Meier C, Parmantier E, Brennan A, et al. Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB[J]. J Neurosci, 1999, 19(10): 3847-3859. DOI: 10.1523/JNEUROSCI.19-10-03847.1999.
[32] Maudsley S, Zamah AM, Rahman N, et al. Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity[J]. Mol Cell Biol, 2000, 20(22): 8352-8363. DOI: 10.1128/MCB.20.22.8352-8363.2000.
[33] Fraenzer JT, Pan H, Minimo L, et al. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation[J]. Int J Oncol, 2003, 23(6):1493-1500.
[34] Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease[J]. Cell, 2017, 170(1): 17-33. DOI: 10.1016/j.cell.2017.06.009.
[35] Maertens O, Cichowski K. An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer[J]. Adv Biol Regul, 2014, 55:1-14. DOI: 10.1016/j.jbior.2014. 04.002.
[36] Drugan JK, Rogers-Graham K, Gilmer T, et al. The Ras/p120 GTPase-activating protein (GAP) interaction is regulated by the p120 GAP pleckstrin homology domain[J]. J Biol Chem, 2000, 275(45): 35021-35027. DOI: 10.1074/jbc.M004386200.
[37] Evans DG, Bowers NL, Tobi S, et al. Schwannomatosis: a genetic and epidemiological study[J]. J Neurol Neurosurg Psychiatry, 2018, 89(11): 1215-1219. DOI: 10.1136/jnnp-2018-318538.
[38] Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis[J]. J Med Genet, 2008, 45(6): 332-339. DOI: 10.1136/jmg.2007.056499.
[39] Nacak TG, Leptien K, Fellner D, et al. The BTB-kelch protein LZTR-1 is a novel golgi protein that is degraded upon induction of apoptosis[J]. J Biol Chem, 2006, 281(8): 5065-5071. DOI: 10.1074/jbc.M509073200.
[40] Abe T, Umeki I, Kanno SI, et al. LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases[J]. Cell Death Differ, 2020, 27(3): 1023-1035. DOI: 10.1038/s41418-019-0395-5.
[41] Smith MJ, Isidor B, Beetz C, et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis[J]. Neurology, 2015, 84(2): 141-147. DOI: 10.1212/WNL.0000000000001129.
[42] Motta M, Fidan M, Bellacchio E, et al. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling[J]. Hum Mol Genet, 2019, 28(6): 1007-1022. DOI: 10.1093/hmg/ddy412.
[43] Nie Z, Xue Y, Yang D, et al. A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex[J]. Mol Cell Biol, 2000, 20(23): 8879-8888. DOI: 10.1128/MCB.20.23.8879- 8888.2000.
[44] Narlikar GJ, Sundaramoorthy R, Owen-Hughes T. Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes[J]. Cell, 2013, 154(3): 490-503. DOI: 10.1016/j.cell.2013.07.011.
[45] Manghera M, Douville RN. Endogenous retrovirus-K promoter: a landing strip for inflammatory transcription factors? [J] Retrovirology, 2013, 10: 16. DOI: 10.1186/1742-4690-10-16.
[46] Cardelli M, Doorn RV, Larcher L, et al. Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients[J]. Epigenomics, 2020, 12(19): 1689-1706. DOI: 10.2217/epi-2020-0127.
[47] Doucet-O'Hare TT, DiSanza BL, DeMarino C, et al. SMARCB1 deletion in atypical teratoid rhabDOId tumors results in human endogenous retrovirus K (HML-2) expression[J]. Sci Rep, 2021, 11(1): 12893. DOI: 10.1038/s41598-021-92223-x.